11beta-HSD1 Inhibitors for Tissue-Selective Metabolic Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions related to 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activity, such as obesity, metabolic syndrome, and glucocorticoid-related disorders, lack effective inhibitors that can specifically target 11β-HSD1 without systemic side effects.
Innovation Solution
Development of novel compounds represented by Formula I, which are effective inhibitors of 11β-HSD1, capable of selectively inhibiting the enzyme's activity in specific tissues, thereby addressing the pathogenesis of metabolic syndrome and related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for 11β-HSD1-related conditions are used, then glucocorticoid levels are reduced, but systemic side effects occur
Solution Approach 1:
The patent develops compounds that selectively inhibit 11β-HSD1 in specific tissues (such as adipose tissue and liver) where the enzyme contributes to metabolic syndrome, while sparing other tissues. This tissue-selective inhibition approach reduces systemic side effects by avoiding glucocorticoid suppression in tissues where it is beneficial, such as the immune system and brain.
2Adaptability or versatility
If 11β-HSD1 is inhibited systemically, then glucocorticoid levels decrease, but tissue-specific effects are lost
Solution Approach 1:
The patent employs structure-activity relationship (SAR) analysis to optimize compound parameters, including substituent groups at specific positions on the core molecular structure. By systematically varying parameters such as R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 substituents, the invention achieves compounds with enhanced tissue selectivity and improved pharmacokinetic properties without excessive structural complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inhibit 11β-HSD1 activity, potentially reducing glucocorticoid levels, improving insulin sensitivity, and treating conditions like obesity, metabolic syndrome, and glucocorticoid-related disorders with reduced systemic side effects.
Implementation Method 1
The compounds effectively inhibit 11β-HSD1 activity, potentially reducing glucocorticoid levels
Data Source
AI summary
This invention relates to novel compounds of the Formula (I), (Ia1-10), (Ib1-10), (Ic1-10), (Id1-7), (Ie1-5) pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11ß-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.